News – Page 467 – Endpoints News

In the middle of an R&D shakeup, Novartis makes a $300M investment in early-stage biologics research tech

3 years ago

Biden turns to biotech for his inaugural ARPA-H director

3 years ago

#ESMO22: Grail puts its cancer test to a real world trial — but it's 'not ready for prime time yet'

3 years ago

#ESMO22: 'End of the beginning': As PD-(L)1s press on, how far can combo therapies take immuno-oncology?

3 years ago

Freshly baked: Pretzel Therapeutics takes out the oven mitts to drug diseases in the powerhouse of the cell

3 years ago

#ESMO22: Amgen spotlights confirmatory win for KRAS G12C player Lumakras in lung cancer — but there's plenty more ...

3 years ago

Here's your invitation to this year's Endpoints 11 awards. Let's celebrate the best of biotech together

3 years ago

#ESMO22: Deciphera pins its comeback hopes on improved TGCT data

3 years ago

#ESMO22: AstraZeneca takes different approach to CTLA-4 with bispecific — but toxicities remain high

3 years ago

Bristol Myers Squibb scores TYK2 OK; ARCH backs mRNA platform play; Illumina’s $8B conundrum; Sizing up Alnylam's ...

3 years ago

Bristol Myers wins a megablockbuster bet with TYK2 FDA approval — and there's a big bonus for the label

3 years ago

Manufacturers sound off on FDA drug reporting guidance, pointing to challenges and recommendations

3 years ago

Colorado to seek FDA approval by fall on Canadian drug imports

3 years ago

Merck Foundation debuts $20M health equity fund focused on cancer care

3 years ago

J&J settles gender discrimination and retaliation allegations involving former CEO and R&D head

3 years ago

$100 for a Covid-19 vaccine? That's what Moderna says may be coming

3 years ago

Pharma companies need to speak the right language to reach growing Hispanic patient populations

3 years ago

Brand name inhalers are very good at blocking competition, better even than nebulizers, study finds

3 years ago

After painful flop late last year, Allakos reveals new PhIII data and pivots to new indications

3 years ago

#ESMO22: Adaptimmune touts new PhI data for its cell therapy treatment

3 years ago

#ESMO22: At five-year mark, Lynparza kept more patients alive than Avastin but missed overall OS significance

3 years ago

Deerfield backs a Penn spinout aiming to shake up Parkinson's treatments using stem cells, brain surgery

3 years ago

#ESMO22: Data on two key checkpoint failures highlight Merck's dominance in adjuvant setting

3 years ago

#ESMO22: Here are the disastrous data that crushed hopes for a $3.6B Bristol Myers combo deal

3 years ago

First page Previous page 464 465 466467468 469 470 Next page Last page